N/A N=154 In-home Obesity Prevention to Reach Low-income Infants
Obesity · Obesity, Childhood · Obesity; Familial
Primary: Mother BMI — 30.6; 34.2; 34; 34.3 kg/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Genetic-specific Effects of Fructose on Liver Lipogenesis
NAFLD
Primary: Mean Change in Liver Fat Content Based on Elastography — -0.15; 1.10 kilopascal (kPa) — p=0.40
N/A N=50 Delivery of Digital Cognitive Behavioural Therapy Following Concussion
Concussion, Mild
Primary: Participant Compliance With HeadOn Program — 45; 5 Participants
Phase 4 N=114 Effect of Perioperative Gabapentin on Postoperative Opioid Requirements
Postoperative Pain
Primary: Opioid Prescription at Discharge — 40; 40; 19; 15 Participants
Phase 2 N=144 Pomalidomide for the Treatment of Bleeding in HHT
Telangiectasia, Hereditary Hemorrhagic
Primary: Change From Baseline Epistaxis Severity Score — -1; -1.1; -1.3; -1.2 units on a scale
N/A N=23 Toward Thriving: A Set of Reflective Tools to Empower Chronic Pain Patients and Help Them Envision a Personal Path to Thriving.
Chronic Pain
Primary: Participants Engaged in the Interventions — 23; 14; 12; 13 Participants
Phase 3 N=303 Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Number of Subjects With Clinical Resolution of Bacterial Conjunctivitis — 71; 59 Participants — p=0.2219
Phase 4 N=15 Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma
Asthma
Primary: Changes in Alpha-diversity of Respiratory Microbiota — 0.13 Shannon's index
N/A N=102 Optimizing Efficiency and Impact of Digital Health Interventions for Caregivers
Family Caregivers · Insomnia · Sleep Initiation and Maintenance Disorders
Primary: SHUTi Engagement — 18; 22; 60 Participants
N/A N=5 A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
Breast Cancer
Primary: Number of Participants Evaluated for Adverse Events — 5 Participants
N/A N=344 The Healthy Weigh Study
Obesity
Primary: Mean Weight Change — -6.86; -6.86; -2.82; -0.66 pounds
Phase 3 N=852 A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16 — 10.0; 43.9; 45.7 percentage of participants — p=<0.001
Phase 3 N=597 Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
Dry Eye Disease (DED)
Primary: Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57 — -2.0; -1.0 units on a scale
Phase 3 N=467 Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
Smallpox
Primary: Cmin — 792 ng/mL
Phase 2 N=321 Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer
Rectal Cancer
Primary: Number of Participants With Disease Recurrence — 53; 39 Participants — p=0.047